Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Subscribe To Our Newsletter & Stay Updated
